Evaluate Severe Hepatic Impairment on Dacomitinib PK

NCT03865446 PHASE1 COMPLETED Results posted

This is a post approval requirement to study the effect of severe hepatic impairment on the pharmacokinetics of dacomitinib.

Details

Lead sponsor	Pfizer
Phase	PHASE1
Status	COMPLETED
Enrolment	16
Start date	Fri Apr 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Oct 24 2019 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Severe Hepatic Impairment

Interventions

• Dacomitinib

Countries

United States